Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy

Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie
Christian KellnerMatthias Peipp

Abstract

In the last two decades, monoclonal antibodies have revolutionized the therapy of cancer patients. Although antibody therapy has continuously been improved, still a significant number of patients do not benefit from antibody therapy. Therefore, rational optimization of the antibody molecule by Fc engineering represents a major area of translational research to further improve this potent therapeutic option. Monoclonal antibodies are able to trigger a variety of effector mechanisms. Especially Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement- dependent cytotoxicity (CDC) are considered important in antibody therapy of cancer. Novel mechanistic insights into the action of monoclonal antibodies allowed the development of various Fc engineering approaches to modulate antibodies' effector functions. Strategies in modifying the Fc glycosylation profile (Fc glyco-engineering) or approaches in engineering the protein backbone (Fc protein engineering) have been intensively evaluated. In the current review, Fc engineering strategies resulting in improved ADCC, ADCP and CDC activity are summarized and discussed.

References

Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Feb 13, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Jul 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Nicola Di GaetanoJosée Golay
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Mar 24, 2004·Trends in Immunology·Kyra A GeldermanArko Gorter
Oct 30, 2004·Biotechnology and Bioengineering·Katsuhiro MoriMitsuo Satoh
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qian GongAndrew C Chan
Dec 3, 2005·Biotechnology Progress·Jason HodoniczkyDavid C James
Dec 3, 2005·Science·Falk Nimmerjahn, Jeffrey V Ravetch
Mar 15, 2006·Journal of Immunotherapy·Karin BarbinGeorg H Fey
Mar 16, 2006·Proceedings of the National Academy of Sciences of the United States of America·Greg A LazarBassil I Dahiyat
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Nov 23, 2006·Methods in Enzymology·Santosh Kumar Patnaik, Pamela Stanley
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Jul 9, 2008·Current Opinion in Immunology·T Shantha Raju
Jul 29, 2008·Current Opinion in Immunology·Leonard G Presta
Feb 28, 2009·Nature Reviews. Drug Discovery·Roy Jefferis
Mar 24, 2009·Lancet·Louis M WeinerSoldano Ferrone
Jun 30, 2009·Journal of Molecular Biology·Matthias J FeigeJohannes Buchner
Sep 10, 2009·Biotechnology and Bioengineering·Patrick H C van BerkelPaul W H I Parren
Nov 10, 2009·Current Opinion in Biotechnology·William R Strohl
Jul 17, 2010·International Journal of Cancer. Journal International Du Cancer·Wei XuJian-Yong Li

❮ Previous
Next ❯

Citations

Mar 15, 2018·Expert Opinion on Investigational Drugs·Roland B Walter
Oct 27, 2017·Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur̈ Transfusionsmedizin Und Immunham̈atologie·Andreas Humpe, Matthias Peipp
Jun 2, 2018·European Journal of Clinical Investigation·Niels Heemskerk, Marjolein van Egmond
Aug 11, 2018·Human Vaccines & Immunotherapeutics·J M L CasanS Opat
Sep 1, 2018·Current Protocols in Pharmacology·Caroline S ColleyTrevor C I Wilkinson
Dec 14, 2018·Oncoimmunology·Ӧzlem TüreciUgur Sahin
Aug 6, 2019·Frontiers in Immunology·Alan L SchmaljohnGeorge K Lewis
Sep 16, 2020·The Journal of Experimental Medicine·Astrid HagelkruysJosef M Penninger
Dec 29, 2019·European Journal of Nuclear Medicine and Molecular Imaging·Camilla ChristensenAndreas Kjaer
Sep 6, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Fang YangJianhua Sui
Oct 14, 2020·Immunological Reviews·Daniela WeschHans-Heinrich Oberg
Dec 18, 2020·Frontiers in Cell and Developmental Biology·Joana MaiaBruno Costa-Silva
Feb 16, 2021·The Journal of Infectious Diseases·Evan RossignolBoris Julg
Feb 20, 2021·Expert Opinion on Biological Therapy·Martin De CeccoLisa L McDermott
Mar 5, 2021·Molecular Cancer·Lien Van HoeckeSandra Van Lint
Oct 31, 2020·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Jatin B TandaleVinod P Gaur
May 24, 2021·Analytica Chimica Acta·Csenge FilepAndras Guttman
Jun 20, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Swetha Lankipalli, Udupi A Ramagopal
Jul 11, 2021·Journal of Controlled Release : Official Journal of the Controlled Release Society·Imke Rudnik-Jansen, Kenneth A Howard
May 8, 2020·Journal of Chemical Information and Modeling·Samo LešnikJanez Konc

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.